

Curriculum Vitae of Roberto Gambino

Contacts

Address: Dept. of Medical Sciences, University of Torino,
Corso Dogliotti 14, 10126 Torino, Italy
Telephone: +39 011 633.5493
E-mail: roberto.gambino@unito.it

Current Position

Associate Professor at Department of Medical Sciences, University of Torino, Italy

Educational Background

- Biological Sciences degree at the University of Turin in 1986. He took his PhD in 1991.
- Ph.D in General Pathology in 1991 at the University of Turin

Academic Appointments in Italy

- 2004-2016 Researcher. University of Turin, Department of Medical Science

Academic Appointments abroad

1990-1991 Research Associate at the Lipoprotein Study Unit of the University of Chicago

Bibliometric indices

SCOPUS: peer-reviewed articles 156; total citations 7097; h-index 42

Awards

- Progress in Lipid Research Top Cited Article 2008 – 2010. Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Progress in Lipid Research 2009; 48 (1);1-26.
- 16-19/11/2006, Bologna: Travel Grant S.I.S.A. XX National Congress of S.I.S.A. (Società Italiana per lo Studio dell'Arteriosclerosi)

Current research topics

The field of his research is diabetes, genetics in diabetes, atherosclerosis, lipidology, lipoprotein metabolism, and insulin-resistance. His research activity in the field of metabolism and physiology has produced papers issued on national and international journals.

Funds

- PRIN 2017: “**Microbiome-tailored food products based on typical Mediterranean Diet components**” (Collaborator)
- PRIN 2010-2011 “Impatto di alimenti funzionali e/o nutraceutici contenenti polifenoli sul metabolismo energetico e glico-lipidico, l'infiammazione subclinica, l'espressione genica e

le modificazioni epigenetiche in modelli sperimentali e nell'uomo". (*Prot. 2010JCWWKM_006*;) (Collaborator)

- Year 2010: Health research project of the region Piedmon "Effects of resveratrol on inflammation in type 2 diabetic patients. A double-blind randomised controlled trial". (RF-2010-2313155) (Collaborator)
- Ex 60% Grant Year 2021: Quorum sensing alkyl quinolones molecules, lipid profile and liver dysfunction in septic shock patients with AKI undergoing renal replacement therapy. Co- Principal Investigator.
- Ex 60% Grant Year 2020: Serum Lumican Levels and Liver hystology in patients with NAFLD /NASH (€3.117,92) - Principal Investigator
- Ex 60% Grant Year 2019: Evaluation of serum cysteine-rich protein 61 levels in patients with NAFLD before and after Curcumin Treatment - Principal Investigator.
- Ex 60% Grant Year 2018: Fibroblast Growth Factor 21 (FGF-21) in Subjects with NAFLD before and after Curcumin Treatment - Principal Investigator
- Ex 60% Grant Year 2016-2017: Impact of Toll-like receptor (TLR)-4 polymorphisms on incretin response to acute, nutrient-induced inflammation in NAFLD. - Principal Investigator
- Ex 60% Grant Year 2015: Interaction of endotoxemia with TLR-4 polymorphisms in determining NAFLD and diabetes. - Principal Investigator
- Ex 60% Grant Year 2014: Curcumin efficacy in the management of Non-Alcoholic Fatty Liver Disease (NAFLD). - Principal Investigator
- Ex 60% Grant Year 2013: "Effect of nonalcoholic fatty liver disease on cardiovascular risk in prehypertensive nonobese non-diabetic subjects without metabolic syndrome".- Principal Investigator

DIDACTIC ACTIVITY

Teacher of Clinical Biochemistry at the Faculty of Medicine, of Medical Biotechnology, and in different Specialization Schools of the University of Turin.

PUBLICATIONS IN THE LAST 3 YEARS:

- *Barutta F, Bellini S, Kimura S, Hase K, Corbetta B, Corbelli A, Fiordaliso F, Bruno S, Biancone L, Barreca A, Papotti MG, Hirsh E, Martini M, **Gambino R**, Durazzo M, Ohno H, Gruden G.* Protective effect of the tunneling nanotube-TNFAIP2/M-sec system on podocyte autophagy in diabetic nephropathy. *Autophagy* 2023; 19: 505-524.
- *Devecchi A, Demasi S, Saba F, Rosato R, **Gambino R**, Ponzo, De Francesco A, Massarenti P, Bo S, Scariot V.* Compositional Characteristics and Antioxidant Activity of Edible Rose Flowers and Their Effect on Phenolic Urinary Excretion. *Pol. J. Food Nutr. Sci.*, 2021; 71:383-392.
- *Barutta F, Kimura S, Hase K, Bellini S, Corbetta B, Corbelli A, Fiordaliso F, Barreca A, Papotti MG, Ghiggeri GM, Salvidio G, Roccatello D, Audrito V, Deaglio S, **Gambino R**, Bruno S, Camussi G, Martini M, Hirsch E, Durazzo M, Ohno H, Gruden G.* Protective Role of the M-Sec-Tunneling Nanotube System in Podocytes. *Journal of the American Society of Nephrology* 2021; 32: 1114-1130.
- *Musso G, Sircana A, Saba F, Cassader M, **Gambino R**.* Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression. *Plos Med* 2020, 17(12): 1-31, e1003461.
- *Musso G, Saba F, Cassader M, **Gambino R**.* Diabetic ketoacidosis with SGLT2 inhibitors.

British Medical Journal, 2020, 371: m4147.

- Cioffi I, **Gambino R**, Rosato R, Properzi B, Regaldo G, Ponzio V, Pellegrini M, Contaldo F, Pasanisi F, Ghigo E, Bo S. Acute Assessment of Subjective Appetite and Implicated Hormones After a Hypnosis-Induced Hallucinated Meal: A Randomized Cross-Over Pilot Trial. *Reviews in Endocrine and Metabolic Disorders*, 2020, 21: 411-420.